Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Apurinic/Apyrimidinic Endonuclease Activity Is Associated with Response to Radiation and Chemotherapy in Medulloblastoma and Primitive Neuroectodermal Tumors
Ist Teil von
Clinical cancer research, 2005-10, Vol.11 (20), p.7405-7414
Ort / Verlag
Philadelphia, PA: American Association for Cancer Research
Erscheinungsjahr
2005
Quelle
MEDLINE
Beschreibungen/Notizen
Purpose: Apurinic/apyrimidinic endonuclease (Ap endo) is a key DNA repair activity that confers resistance to radiation- and alkylator-induced
cytotoxic abasic sites in human cells. We assayed apurinic/apyrimidinic endonuclease activity in medulloblastomas and primitive
neuroectodermal tumors (PNET) to establish correlates with tumor and patient characteristics and with response to adjuvant
radiation plus multiagent chemotherapy.
Experimental Design: Ap endo activity was assayed in 52 medulloblastomas and 10 PNETs from patients 0.4 to 21 years old. Ape1/Ref-1, the predominant
human Ap endo activity, was measured in 42 medulloblastomas by immunostaining. Cox proportional hazards regression models
were used to analyze the association of activity with time to tumor progression (TTP).
Results: Tumor Ap endo activity varied 180-fold and was significantly associated with age and gender. Tumor Ape1/Ref-1 was detected
almost exclusively in nuclei. In a multivariate model, with Ap endo activity entered as a continuous variable, the hazard
ratio for progression after adjuvant treatment in 46 medulloblastomas and four PNETs increased by a factor of 1.073 for every
0.01 unit increase in activity ( P ≤ 0.001) and was independent of age and gender. Suppressing Ap endo activity in a human medulloblastoma cell line significantly
increased sensitivity to 1,3-bis(2-chlororethyl)-1-nitrosourea and temozolomide, suggesting that the association of tumor
activity with TTP reflected, at least in part, abasic site repair.
Conclusions: Our data ( a ) suggest that Ap endo activity promotes resistance to radiation plus chemotherapy in medulloblastomas/PNETs, ( b ) provide a potential marker of treatment outcome, and ( c ) suggest clinical use of Ap endo inhibitors to overcome resistance.